These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9404975)

  • 1. Antifibrinolytics do not reduce transfusion requirements in patients undergoing orthotopic liver transplantation.
    Kufner RP
    Liver Transpl Surg; 1997 Nov; 3(6):668-74; discussion 674-6. PubMed ID: 9404975
    [No Abstract]   [Full Text] [Related]  

  • 2. Pro: Antifibrinolytics are safe and effective in patients undergoing liver transplantation.
    Lerner AB
    J Cardiothorac Vasc Anesth; 2006 Dec; 20(6):888-90. PubMed ID: 17138101
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood conservation in liver transplantation: The role of aprotinin.
    Porte RJ; Hendriks HG; Slooff MJ
    J Cardiothorac Vasc Anesth; 2004 Aug; 18(4 Suppl):31S-37S. PubMed ID: 15368204
    [No Abstract]   [Full Text] [Related]  

  • 4. Con: Antifibrinolytics are not safe and effective in patients undergoing liver transplantation.
    Ramsay MA
    J Cardiothorac Vasc Anesth; 2006 Dec; 20(6):891-3. PubMed ID: 17138102
    [No Abstract]   [Full Text] [Related]  

  • 5. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study.
    Dalmau A; Sabaté A; Koo M; Bartolomé C; Rafecas A; Figueras J; Jaurrieta E
    Liver Transpl; 2004 Feb; 10(2):279-84. PubMed ID: 14762867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrinolytics.
    Schmarts
    Acta Anaesthesiol Belg; 2003; 54(4):319-22. PubMed ID: 14719353
    [No Abstract]   [Full Text] [Related]  

  • 7. Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival.
    Massicotte L; Denault AY; Beaulieu D; Thibeault L; Hevesi Z; Roy A
    Transplantation; 2011 Jun; 91(11):1273-8. PubMed ID: 21617589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprotinin administration and disseminated intravascular coagulation.
    Ramsay MA
    Anesth Analg; 1996 Aug; 83(2):433. PubMed ID: 8694334
    [No Abstract]   [Full Text] [Related]  

  • 9. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrinolytics and cardiac surgery: The past, the present, and the future.
    Aggarwal NK; Subramanian A
    Ann Card Anaesth; 2020; 23(2):193-199. PubMed ID: 32275035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrinolytics in orthotopic liver transplantation: current status and controversies.
    Xia VW; Steadman RH
    Liver Transpl; 2005 Jan; 11(1):10-8. PubMed ID: 15690531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of aprotinin in orthotopic liver transplantation: can its harmful effects offset its beneficial effects?
    Lentschener C; Roche K; Ozier Y
    Anesth Analg; 2005 May; 100(5):1248-1255. PubMed ID: 15845662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic drugs.
    Mannucci PM
    N Engl J Med; 1998 Jul; 339(4):245-53. PubMed ID: 9673304
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood product use during orthotopic liver transplantation.
    Shan WL; Barkun J; Metrakos P; Tchervenkov J; Backman SB
    Can J Anaesth; 2004 Dec; 51(10):1045-6. PubMed ID: 15574559
    [No Abstract]   [Full Text] [Related]  

  • 15. Natural and synthetic antifibrinolytics: inert, poisonous or therapeutic agents?
    Hardy JF; Bélisle S
    Can J Anaesth; 1997 Sep; 44(9):913-7. PubMed ID: 9305552
    [No Abstract]   [Full Text] [Related]  

  • 16. Antifibrinolytics in liver transplantation.
    Groenland TH; Porte RJ
    Int Anesthesiol Clin; 2006; 44(3):83-97. PubMed ID: 16832208
    [No Abstract]   [Full Text] [Related]  

  • 17. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery.
    Mengistu AM; Röhm KD; Boldt J; Mayer J; Suttner SW; Piper SN
    Anesth Analg; 2008 Aug; 107(2):391-7. PubMed ID: 18633013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin.
    Engel JM; Hohaus T; Ruwoldt R; Menges T; Jürgensen I; Hempelmann G
    Anesth Analg; 2001 Mar; 92(3):775-80. PubMed ID: 11226117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of antifibrinolytic agents results in a reduction in transfused blood products during liver transplantation.
    Ramsay MA
    Liver Transpl Surg; 1997 Nov; 3(6):665-8. PubMed ID: 9404974
    [No Abstract]   [Full Text] [Related]  

  • 20. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery.
    Wong BI; McLean RF; Fremes SE; Deemar KA; Harrington EM; Christakis GT; Goldman BS
    Ann Thorac Surg; 2000 Mar; 69(3):808-16. PubMed ID: 10750765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.